H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on TARA stock, giving a Buy rating on April 28.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of Protara Therapeutics’ TARA-002 in the treatment of non-muscle invasive bladder cancer (NMIBC). The updated interim data from the ADVANCED-2 study presented at AUA 2025 underscores TARA-002’s promising efficacy, particularly in BCG-unresponsive patients, where it achieved a 100% high-grade complete response rate at any time. Additionally, the treatment demonstrated a strong safety profile, with most adverse events being mild and transient, and no treatment-related discontinuations or severe adverse events reported.
Furthermore, TARA-002’s catheter-based administration is seen as a significant advantage over device-dependent competitors, making it more appealing to community urologists. The ease of use, coupled with encouraging early response rates and a manageable safety profile, positions TARA-002 as a potential alternative to BCG, especially amid ongoing shortages and tolerability issues. With the upcoming update on the BCG-naïve registrational trial design, there is a meaningful catalyst for commercial success, as TARA-002 could fill critical gaps in the bladder-sparing market, providing a differentiated option for both academic centers and high-volume community practices.
In another report released on April 28, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.